Aspire Biopharma, PowerUp Acquisition complete business combination

Aspire Biopharma (ASBP), a developer of a drug delivery mechanism technology, and PowerUp Acquisition Corp. (PWUP), a Nasdaq Global Market listed special purpose acquisition company, announced the completion of their previously announced business combination. The business combination was approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, and it closed on February 17. Beginning on February 20, Aspire Biopharma shares of common stock and warrants will begin to trade on the Nasdaq Global Market and Nasdaq Capital Market, respectively, under the ticker symbols “ASBP” and “ASBPW,” respectively. “The business combination is expected to provide Aspire Biopharma with improved access to sources of new capital, enable Aspire to further expand the internal development of new product offerings, accelerate strategic partnerships, and fast-absorbing aspirin for use in stopping cardiac incidents which management believes is a candidate for fast-track approval through the FDA,” the company stated.